




Study Summary

With no treatment approved in early 2020 for COVID-19, this is an evaluation of several possible treatments recommended by the UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG):

Randomised Evaluation of COVID-19 ThERapY

Funded by UK Research and Innovation and the National Institute for Health research — the trial treatments are currently used for other conditions so side-effects are well known. No funding comes from the makers of these treatments.

RECOVERY



Patients will join the RECOVERY study with their, or their relatives', consent on admission to hospital with suspected or confirmed COVID-19.

Twice as many patients will get active drugs as get just the standard treatment (the placebo group). The trial has an 'adaptive design' which means that the information collected is reviewed often and changes have been made. For example, a drug that clearly works might quickly start being used for everyone as part of 'standard treatment', another drug that looks promising may be added or a drug that is shown to be harmful or of no use will be discontinued. There have been changes and this summary sheet has been updated (16 June 2020). Information will be collected from patients at a number of hospitals throughout the UK. The information will be collected with as little load on the staff treating patients as possible. No extra blood samples will be taken for this study.

Information on both immediate and longer-term outcomes will be collected in a medical database. These results will be monitored as the research goes along so that they can contribute to national and global advice and approval of future treatments.



Based upon full documentation produced by the study team:
<https://www.recoverytrial.net>

Study Summaries from TrialsConnect are not official information for patients or others. They are prepared to aid clinical trials patients in telling their story to family and lay audiences.